China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced an antibody collaboration, assignment, and exclusive license agreement with compatriot firm Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692). Under the agreement, Biocytogen will provide a license to Hansoh to use selected fully human antibody molecules against a designated target for global development, manufacturing, and commercialization.
Agreement Details
Biocytogen will receive an upfront payment and will be eligible to receive development and commercial milestones of up to tens of millions of Chinese renminbi, as well as single-digit tiered royalties on net sales. This strategic partnership aims to leverage Biocytogen’s innovative antibody technology and Hansoh’s development and commercial capabilities to advance the selected antibody molecules globally.
Antibody Selection and Technology
The licensed antibodies were selected from Biocytogen’s Project Integrum programs and generated from their proprietary fully human antibody RenMice target-knockout mice. This technology platform enables the discovery and development of high-quality fully human antibodies, positioning the licensed molecules for potential success in addressing significant unmet medical needs.-Fineline Info & Tech
